Thus, our results suggest that NSCLC patients with PD-L1 negative profiles may be evaluated for PD-L2 expression and postulates that PD-L2 may be used as a new target for this group of patients. This evidence concerns the gene PDCD1LG2 and non-small cell lung carcinoma.